Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4359 studies found for:    "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Recruiting Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Follicular Lymphoma, Grade 3b;   Transformed Lymphoma / DLBCL
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
2 Recruiting PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis
Conditions: Primary Myelofibrosis;   Myeloproliferative Disorders
Interventions: Procedure: Allogeneic hematopoietic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Drug: Ruxolitinib
3 Recruiting GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Conditions: Leukemia, Acute Lymphoblastic;   Acute Myeloid Leukemia;   Mixed-Lineage Acute Leukemias
Interventions: Procedure: Allogeneic stem cell transplantation;   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Bendamustine
4 Recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
5 Active, not recruiting Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immune System Diseases
Interventions: Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Procedure: Allogeneic hematopoietic stem cell transplantation
6 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
7 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
8 Completed A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Conditions: Ovarian Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
9 Completed A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
Condition: HIV Infections
Interventions: Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: Filgrastim;   Drug: Stavudine;   Drug: Cyclophosphamide
10 Completed A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoplasms;   Neoplasms by Site;   Breast Diseases;   Skin Diseases
Intervention: Drug: ET743
11 Not yet recruiting Disulfiram in Recurrent Glioblastoma
Conditions: Glioma;   Glioblastoma
Interventions: Drug: Disulfiram;   Dietary Supplement: Copper;   Drug: Alkylating Agents
12 Not yet recruiting Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Conditions: Primary Effusion Lymphoma;   B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Prednisone;   Drug: Etopside;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
13 Recruiting Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Epirubicin 90 mg/m2 iv;   Drug: Cyclophosphamide 600 mg/m2 iv;   Drug: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv;   Drug: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only);   Drug: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only);   Dietary Supplement: Tocotrienol 300 mg x 3 daily
14 Recruiting Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Conditions: Multiple Myeloma;   Amyloidosis
Interventions: Device: Melphalan;   Drug: Pegfilgrastim;   Procedure: Autologous Hematopoietic Progenitor Cell Transplant
15 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
Condition: Hepatocellular Carcinoma
Interventions: Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
16 Recruiting Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide;   Drug: pirarubicin and cyclophosphamide
17 Recruiting Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Conditions: Glioblastoma;   Malignant Glioma
Interventions: Drug: Marizomib;   Drug: Temozolomide;   Radiation: Radiation Therapy
18 Recruiting Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23
Condition: Ovarian Neoplasms
Interventions: Drug: Trabectedin;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Topotecan;   Drug: Gemcitabine;   Drug: Weekly Paclitaxel;   Drug: Carboplatin
19 Not yet recruiting Nivolumab in Relapsed Pediatric Solid Tumors
Condition: Antibodies, Neoplasm
Intervention: Drug: Nivolumab,low dose cyclophosphamide
20 Completed Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status
Conditions: Glioblastoma Multiforme;   Primary Brain Tumor
Interventions: Drug: Temozolomide;   Drug: Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years